In-Vivo Mouse Brain Diffusion Tensor Magnetic Resonance Imaging (DT-MRI) Detects Gender and Region Specific Pathology Induced by Cuprizone

L-A. Harsan¹, Y. Sun¹, N. Baxan¹, J. Hennig¹, and D. von Elverfeldt¹

¹Department of Diagnostic Radiology, Medical Physics, University Hospital, Freiburg, Germany

Introduction:

Multiple Sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS), with a large heterogeneity in clinical course, MRI patterns and responses to therapy. It is characterized by extensive loss of myelin in acute or chronic plaques, as well as by axonal injury and inflammation. Clinical observations show that the course of MS is gender dependent, women reach disability milestones at older ages than males and the male sex is associated with a more progressive and severe outcome than female sex^{2,3}. The question of "why these gender differences in MS" was mainly addressed by the examination of hormonal influences in animal models but no in vivo longitudinal brain imaging study, meant to characterize the brain microstructure in demyelinating males and females was carried out till now. In mice, the cuprizone diet model^{4,5} raised particular interest because it underlines the progression of acute demyelinating pathology to the chronic state. By using brain diffusion tensor magnetic resonance imaging (DT-MRI) in the cuprizone mouse model we aimed to characterize the region specific vulnerability of the brain tissue to cuprizone (especially in the early phase of the disease) and to identify in vivo the pattern of microstructural changes overtime, comparatively, in male and female mice.

Materials and Methods:

Male and female 8-week old C57BL/6 mice were treated with 0.2% cuprizone for 12 weeks, underlining the progression of active demyelinating processes towards the chronic state. In vivo brain DT-MRI exams were performed at different time points (week 0 before cuprizone treatment, w4, w8 and w12 - 4, 8 and 12 weeks after starting the cuprizone diet) as presented in the Figure-A. Duplicates for each group were kept in the same conditions of housing and treatment and used for the histopathological examination. MRI: The mice were scanned under isoflurane anesthesia, using a 9.4T small bore animal Scanner (Biospec 94/20, Bruker, Germany). A transmit/receive 1H mouse quadrature birdcage resonator (35 mm inner diameter) was used for data acquisition. A RARE T2weighted sequence was employed to obtain 31 axial slices (78x78x500µm³) with the following parameters: TR/TE = 4200/35 ms, a RARE factor of 4 and NEX= 4. Mouse brain DT-MRI was performed using a 4-shots DT-EPI sequence. Diffusion gradients were applied in 45 non-collinear directions for a b factor of 1000s/mm². The brain axial slices were acquired with TR/TE = 5000/30 ms, time (Δ) between the application of diffusion gradient pulses of 17ms, diffusion gradient duration (δ) of 7ms. The in-plane image resolution was 156 x 156 μm at a FOV=20 x 20 mm and an acquisition matrix of 128x92. Partial Fourier with an acceleration factor of 1.35 and 31 overscan lines were used. The movement artifacts were avoided by performing respiratory gating. The total acquisition time varied in a range of 1h39min – 2h15min, depending on the respiratory rhythm of the animal. The diffusion tensor was calculated using in house developed DT-MRI software. Different diffusion tensor parametric maps were generated, including fractional anisotropy (FA), mean diffusivity <D>, radial (D⊥) and axial diffusivity (D_{||}) as well as directional encoded images. The values of these parameters were assessed in different ROIs of white (WM) and gray matter (GM), comparatively in males and females, and statistical analysis was performed at different scanning points. DT-MRI results were further correlated with the histological evaluation, assessing the myelin and axonal state and the modifications in the glial cell population (oligodendrocytes, astrocytes).

Results and Discussion:

Cuprizone treatment induced marked white matter (WM) pathology: region specific oligodendrocyte depletion, gliosis, demyelination and axonal damage. These pathologic alterations, observed starting with the early phase (week 4) of the disease, caused changes of DT-MRI derived parameter values. DT-MRI evidenced high vulnerability of the rostral external capsule at w4 (red arrows, ec, Fig. B), with subtle differences quantified between male and female brains. In the rostral part of the male brain, FA decreased in the major WM areas (genu of the corpus callosum-gcc, external capsule-ec and anterior commissureac), while in females the most affected region was the external capsule (Fig.-B, FA). The early differences between males and females could also be seen in color coded and T2weighted images (w4, Fig.-B, arrows). At this timepoit, the axial diffusivity values drastically decreased (e.g. Fig-F, w4) from normal (Fig-F, w0) in both male and female corpus callosum (cc), with stronger decline observed in the male's WM (Fig-D). Axonal damage and gliosis observed in histopathological investigation accounted for the abnormally low values of axial diffusion. The assessment of the radial diffusivity overtime showed a faster progression towards abnormally high values in male white matter, when compared with data obtained from females. At w12, D₊ values calculated in the corpus callosum of the male mice were significantly higher than those obtained in females, suggesting a more severe demyelinating phenotype. The increased values of D⊥ correlated with the oligodendrocyte apoptosis and the myelin loss. At the chronic phase of the disease (w12), enlarged ventricles and infiltration of the cerebrospinal fluid in the surrounding tissue were observed in both genders. This aspect of the pathology occurred with higher frequency and from earlier phases of the pathology (w4 or w8) in males. The gender specific WM abnormalities were evidenced also in the color coded maps (Fig.-E, white arrows) acquired from more caudal part of the brain and describing the fiber's orientations. Fiber tracking was also performed, helping to assess the impact of demyelinating pathology on fiber's architecture and integrity.

DT-MRI DT-MRI DT-MRI DT-MRI Histo Histo Histo Histo Group 1: 10 males Group 2: 10 females w4 w8 Cuprizone 0.2% (demyelinated mice) w12 w0 Control groups: Group 3: 10 males WO Group 4: 10 females Normal Diet (Control mice) A. Experimental design Females Males W4 W0 before cuprizone before cuprizone Color-coded Fractional anisotropy T2-weighted **B**.Comparison between male and female brains at w0 and w4 **Evolution of Radial Diffusivity values** Axial diffusivity, W4 during Cuprizone Treatment x10-3 mm²/s Control values ć10-3 0.6 values % 0,9 **m** 0,9 0.2 0.7 w12 Genu of the co **D.** Statistical significant C. Higher values of D_⊥ are observed in differences in D_∥ values nales cc, in early (w4) and late phase of are seen at w4, between he disease(w12). nale and female WM W0 F. The strong decrease of the axial diffusivity values E. Subtle differences are seen between at w4 (see red arrows) was male and female brains in color coded correlated with the axonal maps at week 4 (w4) - see arrows.

damage seen in histology.

Conclusion: The combination of in vivo DT-MRI and histology allowed the characterization of region specific vulnerability of the WM to cuprizone and provided evidences of subtle differences in the acute and chronic demyelination pattern between male and female mice. When compared with females, the progressing pathology in the male brains had a stronger impact on the values of DT-MRI derived indices (e.g. D⊥ and D_{||}), suggesting a faster and more severe course of the disease. The female sex hormones might play an important protective role in early phases of demyelinating disorders and could be exploited for the development of treatments. The existence of a sexual dimorphism in demyelination processes implies also a gender specific response to different therapeutic strategies developed to induce remyelination.

Kornek B, Lassmann H. Brain Res Bull 2003; 61: 321-326. ²Confavreux et al., Brain(a) 2006; 129: 595-605. ³Confavreux C, Vukusic S. Brain 2006b; 129: 606-616. ⁴ Matsushima GK, Morell P.Brain Pathol 2001; 11: 107-116. ⁵ Harsan et al., J Neurosci. 2008: 28(52):14189-201